INVEA
Live / Allowed — Second extension granted (statement of use) (as of 12 Oct 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 03 Apr 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 97869600
- Mark type
- Word mark
- Filed
- 03 Apr 2023
- Published for opposition
- 19 Aug 2025
- Attorney of record
- Jonathan Harris
Goods and services
- Class 001 — Chemicals: Biochemical preparations for the treatment of inflammatory diseases and disorders, including the central nervous system, enteric nervous system, immune system, gastrointestinal tract and dermatologic diseases and disorders, including atopic dermatitis, chronic urticaria, and prurigo nodularis; all these goods excluding food supplements, dietetic food preparations and ingredients and other dietetic products
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of gastrointestinal and hepatobiliary diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders and diseases relating to the gut-brain axis, involving the central nervous system, enteric nervous system, immune system, gastrointestinal tract, and dermatology; chemical preparations for the treatment of inflammatory diseases and disorders, including the central nervous system, enteric nervous system, immune system, gastrointestinal tract and dermatologic diseases and disorders, including atopic dermatitis, chronic urticaria, and prurigo nodularis ; biological preparations for the treatment of inflammatory diseases and disorders, including the central nervous system, enteric nervous system, immune system, gastrointestinal tract and dermatologic diseases and disorders, including atopic dermatitis, chronic urticaria, and prurigo nodularis; Pharmaceutical preparations for the treatment of gastrointestinal and hepatobiliary diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and immune system-related disorders; Pharmaceutical preparations in the field of gastrointestinal and hepatobiliary diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and immune system-related disorders; all these goods/services excluding food supplements, dietetic food preparations and ingredients and other dietetic products; the mark is used as a house mark for the goods identified in the instant application
Owner
- Invea Therapeutics, Inc., Guilford, CT, US
- Invea Therapeutics, Inc., Guilford, CT, US
Prosecution history
- 13 Oct 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Oct 2026 — SOU EXTENSION 2 GRANTED
- 12 Oct 2026 — SOU EXTENSION 2 FILED
- 12 Oct 2026 — SOU TEAS EXTENSION RECEIVED
- 14 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Apr 2026 — SOU EXTENSION 1 GRANTED
- 13 Apr 2026 — SOU EXTENSION 1 FILED
- 13 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Oct 2025 — CORRECTED NOA E-MAILED
- 28 Oct 2025 — POST PUBLICATION AMENDMENT - ENTERED
- 23 Oct 2025 — ASSIGNED TO PETITION STAFF
- 14 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Sept 2025 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 19 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Aug 2025 — PUBLISHED FOR OPPOSITION